4Sc AG logo

VSC - 4Sc AG News Story

€1.41 0.0  2.2%

Last Trade - 13/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £59.9m
Enterprise Value £30.2m
Revenue £1.93m
Position in Universe 795th / 1053

BRIEF-4SC Expects To Continue To Report Annual Net Losses

Wed 25th March, 2020 6:38am
March 25 (Reuters) - 4SC AG  VSCk.DE :
    * PROVIDES RESULTS FOR FINANCIAL YEAR 2019 AND OUTLOOK
    * SUPPLY DEAL WITH MERCK KGAA ENABLES MERKLIN 2 STUDY TO
COMMENCE
IN 2020
    * FOR 2020, 4SC ESTIMATES NET LOSS TO NEARLY DOUBLE COMPARED
TO
2019 AS IT PLANS TO INCREASE CLINICAL ACTIVITIES FOR ITS MAIN
DRUG CANDIDATES SIGNIFICANTLY IN ACCORDANCE WITH ITS BUSINESS
PLAN
    * 4SC EXPECTS TO CONTINUE TO REPORT ANNUAL NET LOSSES, WITH
ALMOST
IDENTICAL FUNCTIONAL COST ALLOCATIONS, IN SHORT TO MEDIUM TERM
FUTURE
    * COMPLETE PHASE IIA PART OF EMERGE STUDY IN MICRO-SATELLITE
STABLE GASTROINTESTINAL CANCER
    * INITIATE (FIRST PATIENT ENROLLED) OF PHASE IIB PART OF
EMERGE
STUDY
    * MANAGEMENT BOARD ESTIMATES THAT CURRENT FUNDS SHOULD BE
SUFFICIENT TO FINANCE 4SC INTO SECOND HALF OF 2021

Source text for Eikon:  ID:nEQGzGKya 
Further company coverage:  VSCk.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.